Wedemeyer, HeinerYurdaydin, CihanZachou, KalliopiErhardt, AlexanderDrebber, UlrikeCakaloglu, YaDegertekin, Ha2024-04-242024-04-2420060270-9139https://hdl.handle.net/11468/2308057th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases -- OCT 27-31, 2006 -- Boston, MA[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremiaPegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremiaConference Object444553A554AWOS:000241362302075Q1